Display options
Cite
Nastoupil LJ, Shenoy PJ, Ambinder A, et al. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma. 2014;56(2):383-9doi: 10.3109/10428194.2014.921296.
Nastoupil, L. J., Shenoy, P. J., Ambinder, A., Koff, J. L., Nooka, A. K., Waller, E. K., Langston, A., Seward, M., Kaufman, J. L., Bernal-Mizrachi, L., King, N., Lechowicz, M. J., Lonial, S., Sinha, R., & Flowers, C. R. (2015). Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leukemia & lymphoma, 56(2), 383-9. https://doi.org/10.3109/10428194.2014.921296
Nastoupil, Loretta J, et al. "Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma." Leukemia & lymphoma vol. 56,2 (2015): 383-9. doi: https://doi.org/10.3109/10428194.2014.921296
Nastoupil LJ, Shenoy PJ, Ambinder A, Koff JL, Nooka AK, Waller EK, Langston A, Seward M, Kaufman JL, Bernal-Mizrachi L, King N, Lechowicz MJ, Lonial S, Sinha R, Flowers CR. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma. Leuk Lymphoma. 2015 Feb;56(2):383-9. doi: 10.3109/10428194.2014.921296. Epub 2014 Jul 17. PMID: 24828864.
Copy Download .nbib Format: NLM
Share it on

Leuk Lymphoma. 2015 Feb;56(2):383-9. doi: 10.3109/10428194.2014.921296. Epub 2014 Jul 17.

Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.

Leukemia & lymphoma

Loretta J Nastoupil, Pareen J Shenoy, Alex Ambinder, Jean L Koff, Ajay K Nooka, Edmund K Waller, Amelia Langston, Miray Seward, Jonathan L Kaufman, Leon Bernal-Mizrachi, Nassoma King, Mary Jo Lechowicz, Sagar Lonial, Rajni Sinha, Christopher R Flowers

Affiliations

  1. Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine , Atlanta, GA , USA.

PMID: 24828864 DOI: 10.3109/10428194.2014.921296

Abstract

Mantle cell lymphoma (MCL) remains incurable with conventional chemotherapy without consensus on the optimal initial treatment. We examined our single center experience with frontline therapy for patients with MCL in consecutive cases diagnosed 1995-2011. Among 81 patients, median age was 59 (28% were ≥65 years of age), 95% had stage III/IV disease and 54% had a low risk MCL International Prognostic Index score. Thirty-five percent (n=28) received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and 65% received R-HCVAD (rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with high-dose methotrexate/cytarabine; n=53). Forty-one patients were consolidated with autologous stem cell transplant (ASCT). There were no significant differences in 2-year survival for R-CHOP versus R-HCVAD (p=0.10) or for ASCT versus observation (p=0.06). After controlling for clinical factors, R-HCVAD followed by ASCT was associated with superior progression-free survival (hazard ratio 0.26, 95% confidence interval 0.09-0.75).

Keywords: Mantle cell lymphoma; R-CHOP regimen; R-HCVAD regimen; autologous transplant; outcomes

MeSH terms

Publication Types